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Leucocyte function-associated antigen 1 (LFA-1; 
also known as CDlla/CD18) belongs to the 
family of integrins which is one of the most 
important families of cell adhesion molecules 
and includes receptors that bind to the extra­
cellular matrix as well as receptors involved in 
cell-cell interactions. Recent findings have 
demonstrated that integrins are both adhesion 
receptors and signalling molecules. LFA-1 plays 
a crucial role in many cellular processes (migra­
tion, antigen presentation, cytotoxicity, cell pro­
liferation, haemopoiesis) by mediating cell-cell 
adhesion by binding to ligands such as inter­
cellular adhesion molecules 1, 2 and 3 (ICAM-1, 
-2 and -3) [1]. All integrins are a/i heterodimers, 
with the a-subunit non-covalently associated with
to or within the EF-hand-like motifs located in 
the N-terminal half of the a-subunit with simi­
larity to motifs in classical Ca2+-binding proteins, 
such as calmodulin [6,7]. The second is made up 
of sequences located in a region of approx. 200 
residues, designated the A or inserted (I) 
domain, located in the a-subunit. The I-domain 
is structurally similar to the ligand-binding 
domain in von Willebrand factor, complement 
factors B and C2 and cartilage matrix protein
[8-10]. Only a few integrins (/72, <*i/7i, a2/ii) con­
tain an I-domain. Analysis of recent crystal struc­
tures of the I-domain of aM revealed a conserved 
DXSXS motif which forms a Mg2+ co-ordination 
, which is also termed the metal-ion-
dependent adhesion site (MIDAS) [11]. Muta-
a /7-subunit [21.
accor
çrins can be grouped into 
to a common /7-subunit
[3]. Leucocytes express /7i (VLAs), /72 (Leu- 
CAMs, CD ll/C D  18) and /77 (homing) integrins. 
LFA-1 belongs to the subfamily of /72 integrins,
Mac-1 (a M/?2; CDllb/CD18),which
p i50,95 (ax/72; CD 11 c/CD 18) and aD (a„/i2;
expressed by
tion of the MIDAS co-ordination 
abrogates ligand binding [12-14], demonstrating 
that bivalent cations are critical for interaction of
integrins with their
is a 200-amino
[15]. The third
sequence located 
N-terminal of the cysteine-rich domain that is 
highly conserved in /7-subunits and shows simi-
leucocytes [4,5].
Integrin structure/ligand-binding sites
Ligand-binding
have recently Three
regions of LFA-1 are involved in ligand binding 
(Figure 1). The first consists of sequences close
Structure of the a- and /7-subunits of LFA-1
TM, transmembrane domain; EF hand, EF-hand-like motifs 
involved in cation binding; MIDAS, metal-ion-dependent adhesion 
site; cysteine, cysteine-rich domain; 200 M , a highly conserved 
200-amino acid sequence, containing the MIDAS-like sequence.
COOH EP-hands I domain NH2
Abbreviations used: LFA-1, leucocyte function-associ-
ICAM, intercellular
*  • m e t a 1 - i o n -d e p e n d e n t c
FAC, focal adhesion complex.
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binding residues by steric hindrance or by alter­
ing the conformation of the residues. ICAMs are 
known to use an LDV sequence for integrin 
binding (amino acids IETP in ICAM-1 and 
LETS in ICAM-2 and ICAM-3). How precisely
these motifs interact with the various sites in the
Although the cytoplasmic tails of the a- and 
/j-subunits of integrins are relatively short (58 
and 46 amino acids respectively), several 
sequences within them have been implicated in 
the alterations that occur in integrin 
Deletion of a stretch of five amino acids contain-
I-domain is not yet clear and awaits the produc- ing three adjacent threonines and phenylalanine
tion of I-domain-ligand co-crystals. in the C-terminal part of the cytoplasmic
Regulation of integrin function
domain has shown that this sequence is required
LFA-1-ICAM-1 binding [33,34]. PMA-
induced triggering of LFA-1-mediated adhesion,
Leucocytes normally circulate in the bloodstream which activates protein kinase C, results in phos
as non-adherent but
tissue damage and wound healing, they must be 
recruited to sites of inflammation. A feature of 
integrins is their ability to rapidly and reversibly
phorylation of Ser-756 in the cytoplasmic tail of
the /i2 subunit. However, mutation of this serine 
residue has demonstrated that phosphorylation is 
not crucial for the affinity modulation of LFA-1
modulate the level of adhesiveness. Integrins play [34]. Recently, a regulatory protein
an essential role in the two-way communication 
between the interior of a cell and its extracellular 
environment. In response to signals from the 
cytoplasm or from interaction with the extra­
cellular ligand, adhesiveness can be regulated via 
conformational alterations, such as changes in 
avidity (multivalency) and affinity of the integrin, 
with no change in surface density of the adhesion 
molecules [25,26]. When changes in both avidity 
and affinity occur, integrins can strongly bind
their ligands*o t h at generate
/j2-integrin-mediated adhesion will be discussed 
below.
Affinity regulation
On most cells, integrins are of low affinity and do 
not bind to their ligands. The affinity of integrins 
for their ligands is controlled by intracellular sig-
nals that activate integrins,
[27] •
so-called 
physiological
conditions, cross-linking of the T-
C D 3 generi 'S iritrace 11 u 1 ar signals
a transient LFA-1
[28,29]. This in
tional changes in LFA-1 generated through 
cytoplasmic tails in response to intracellular 
nailing. Activation of protein kinase C and eleva­
tion of intracellular cAMP, Ca24 and lipid levels 
have been demonstrated to result in activation of
LFA-1 [30,31]. Most of these intracellular e
also lead to i
♦ H P  1rins. 1 he
changes in ß\ and ß7 i
LFA-1 are
accompanied by Mg21 - 
changes, which can be detected by 
the 24 epitope [32].
of
has been identified that specifically interacts with 
the cytoplasmic tail of /i2 integrins. Expression of 
this protein enhances /?2-integrin-mediated adhe­
sion [35]. A conserved membrane-proximal 
region of the cytoplasmic /i-subunit (LLvXIhDR; 
less conserved amino acids are shown as lower 
case, and X indicates a non-conserved residue) 
affects heterodimer affinity and specificity 
[36,37], and appears to interact with the con-
membrane-proximal site in the a-chain
(GFFKR) o f
in mcreas
sc conserved
affi-
nity, suggesting that the conserved membrane- 
proximal region of the integrin cytoplasmic 
domains may serve to constrain these receptors 
into a default low-affinity conformation [39].
Avidity regulation
Integrin-ligand interaction can also be regulated
in cell-surface distribution of
•ing of LFA-1 on acti-integrin
Vi
r  1 1  
1 -
has
I CAM-1
that Ca21
r. and it
is involved
[40]. With the use of the anti-LFA-la antibody
a Ca21 -dependent 
has
NKI-L16, which
epitope on GDI la, 
that binding of Ca21 to LFA-1 is associated with 
multimerization of LFA-1 on the cell surface of 
activated T-eells [25,26]. Since there is evidence 
that ICAM-1 is naturally found as a dimer, 
ligand binding may also induce LFA-1 dimeriza- 
tion [41]. Similarly, clustering of Mac-1 has 
reported to correlate with its ability to 
ligand [42]. Evidence is now emerging that 
interaction of integrins with the cytoskeleton may
distribution on the cell surfi
1997
Biochemical Society Transactions
may thus affect the avidity ligand
interactions. Accumulation of cytoskeletal pro­
teins, such as oc-actinin, F-actin, vinculin, pazil- 
lin, talin and filamin, into focal adhesion 
complexes (FACs) requires the combination of 
both aggregation of the integrin receptor by anti­
bodies and ligand binding [43]. Integrins associ­
ate with different cytoskeletal components 
(oc-actinin, talin) and focal adhesion kinase 
(ppl25/,MK), in particular through the cytoplasmic
tail of the 8 conserved region
(EYRRFEKE), N-terminal of the /?2 cytoplasmic 
tail, appears to be critical not only for interaction 
with the cytoskeleton but also for endoplasmic 
reticulum retention, assembly and transport to
the cell membrane of LFA-1 F371. Mutation
three threonines results in impaired spreading 
and decreased ability to form FACs and to 
organize the cytoskeleton into stress fibres [45]). 
A conserved NPXY motif in the /?-chain has been 
implicated in the localization in FACs [36].
Coupling and uncoupling integrins to and 
from the cytoskeletal elements provides leuco­
cytes with a mechanism of locomotion. The 
cytoskeleton or associated molecules may act as a 
repressor and prevent alteration of the affinity
state of LFA-1; thus activation of LFA-1 would 
require uncoupling from the cytoskeletal ele­
ments (derepression). We have indeed observed 
that uncoupling of LFA-1 from the cytoskeletal
network, 
movement
cytochalasin D, facilitates lateral 
LFA-1 (cluster formation), which
results in high avidity and sequentially high-affi- 
nity ligand interaction on resting leucocytes [46]. 
Dynamic interaction of integrins with the cyto­
skeleton has recently also been demonstrated by 
others, showing that uncoupling of [i\ integrins 
from the cytoskeleton by cytochalasin D
motility
PMA
cates that the cytoskeleton actively maintains 
LFA-1 in its non-adhesive state and that release 
from the cytoskeletal constraints is indeed an 
important early step in activation of adhesion.
Post-ligand signalling through integrins 
upon ligand binding
Besides regulation of the adhesion receptor by 
signals generated inside the cell, increasing 
evidence is emerging that adhesion receptors can 
also transmit signals into the cell. This so-called 
‘outside-in’ signalling by integrins has been 
shown by the use of monoclonal antibodies or 
immobilized ligands to cross-link integrin recep-
tors. Cross-linking of integrins by their ligands 
results in cellular functions such as programmed 
cell death (apoptosis), cytotoxicity, proliferation, 
differentiation, antigen presentation and specific 
transcriptional regulation of target genes and
cytokines [30,48].
Cross-linking of LFA-1 by antibodies trig­
gers phosphorylation of phospholipase C-yl, 
ZAP-70 and an 80 kDa protein [49]. We recently 
observed that binding of LFA-1 to only ICAM-1 
and not to ICAM-3 generates tyrosine phos­
phorylation of distinct proteins (Y. van Kooyk, 
unpublished work). Interaction of (3\ integrins 
with extracellular matrix has been shown to 
induce rapid tyrosine phosphorylation of several 
proteins including ppl25/vl/c (focal adhesion 
kinase of 125 kDa), paxillin, tensin and the Src 
family of kinases such as pi30<m [50]. Further­
more LFA-1 cross-linking results in a rise in 
intracellular Ca2+ levels and pH [31]. ppl25/vlK 
has been shown to bind to the cytoplasmic tail of 
Pi integrins and to associate with two non-recep­
tor protein tyrosine kinases, pp60s" and pp59^v", 
via their SH2 domains [51]. Other signalling 
pathways, stimulated through clustering of cer­
tain /?) integrins, are: ERK and JNK signalling 
pathways [43], activation of Rho and pl90-B, a 
new member of the Rho GAP family of the sig­
nalling molecules, and integrin-linked kinase, a 
new 59 kDa threonine-serine kinase that associ­
ates with the cytoplasmic tail of the ¡i\ subunit. 
Binding to fibronectin results in down-regulation 
of kinase activity of this integrin-linked kinase
(p59//A). It is now thought that it is not ppl25MA:
ƒ  ƒ  f  F
but p59 v that is the most receptor-proximal 
protein kinase in the regulation of integrin-medi- 
ated signal transduction.
In conclusion, integrin function is not 
limited to adhesion but they simultaneously also 
act as signal tranducers. The adhesive properties 
of integrins are controlled by altering both their 
avidity and affinity either from the outside of the 
cell or through intracellular pathways. In these 
processes the short cytoplasmic domains associ­
ate with different cytoskeletal proteins, protein 
tyrosine kinases and many other signalling mole­
cules, resulting in a cascade of intracellular sig­
nals. Possible functions of the cytoplasmic tail of 
integrins are: (1) attachment to the cytoskeleton
(e-g- tensin, talin, paxillin, vinculin and
a-actinin); (2) interaction with signalling compo­
nents such as protein kinases and phosphatases
(e.g. p59//A, ppl25/, |/c and CD45); (3) control of
cell adhesion, by altering the avidity of the integ-
Voiume 25
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rin by changing its extracellular conformation 
(clustering); (4) modulation of the ligand-bind­
ing affinity of the integrin.
1 Binnerts, M. E., van Kooyk, Y., Simmons, D. L.
2155-2160
J
2 Hynes, R. O. (1987) Cell 48, 549-554
3 Stewart, M., Thiel, M. and Ilogg, N. (1995) Curr. 
Opin. Cell Biol. 7, 690-696
:hez-Madrid, F., Krensky, A. M., Ware, C. F.,
ins, E., S
4
............................... .......  " ' ----------------------- -- 7 ”  ’  ? ------
^  a -__._ . . . .  t .
ir, J. L., Burakoff, S. J. and 
ringer, T. A. (1982) Proc. Natl. Acad. Sci. 
U.S.A. 79, 7489-7493
5 Vandervieren, ML, Letrong, II., Wood, C. L.,
P. F., Stjohn, T., Staunton, D. E. and
Gallatin, W. M. (1995) Immunity 3, 683-690
6 Tuckwell, I). S., Brass, A. and Humphries, M. J.
(1992) Biochem. J. 285, 325-331
7 Stanley, P., Bates, P. A., Harvey, J., Bennett, R. I. 
and Hogg, N. (1994) EMBO J. 13, 1790-1798
8 Larson, R. S., Corbi, A. L., Berman, L. and 
Springer, T. (1989) J. Cell Biol. 108, 703-712
9 Landis, R. C., Bennett, R. I. and Hogg, N. (1993) 
J. Cell Biol. 120, 1519-1527
10 Randi, A. M. and Hogg, N. (1994) J. Biol. Chem. 
269, 12395-12398
11 Lee, J. ()., Rieu, P., Arnaout, M. A. and 
Liddington, R. (1995) Cell 80, 631-638
12 Michishita, M., Videm, V. and Arnaout, M. A.
(1993) Cell 72, 857-867
13 Kamata, T., Puzon, W. and Takada, Y. (1994)
J. Biol. Chem. 269, 9659
14 Edwards, C. P., Champe, M., Gonzalez, T., 
Wessinger, M. K., Spencer, S. A., Presta, L. G., 
Berman, P. W. and Bodaiy, S. C. (1995) J. Biol. 
Chem. 270, 12635-12640
15 Fuortes, ML, Jin, W. W. and Nathan, C. (1994)
J. Cell Biol. 127, 1477-1483
16 Loftus, J. C., Smith, J. W. and Ginsberg, M. II.
(1994) J. Biol. Chem. 269, 25235-25238
17 Bajl, M. L., Goodman, T. and Mieguire, S. L.
(1995) J. Biol. Chem. 270, 94-98
18 Bajt, M. L. and Loftus, J. C. (1994) J. Biol. Chem. 
269, 20913-20919
19 Kamata, '1'., Wright, R. and Takada, Y. (1995)
J. Biol. Chem. 270, 12531-12535
20 Huang, C. and Springer, T. A. (1995) J. Biol.
Chem. 270, 1 9 0 1 6
21 Champe, ML, McIntyre, B. W. (1995) J. Biol. Chem.
270, 1388-1394
22 Qu, A .1). and Leahy, I). J. (1995) Proc. Natl. Acad.
Sci. U.S.A. 92, 10277-10281
23 Binnerts, M. E., Vankooyk, Y., Edwards, C. P., 
Champe, M., Presta, L., Bodary, S. C., Figdor,
C. G. and Berman, P. W. (1996) J. Biol. Chem. 271,
24 van Kooyk, Y., Binnerts, M. E., Edwards, C. P.,
W
J 1252
25 Lub, M., van Kooyk, Y. and Figdor, C. G. (1995)
26
Immunol. Today 16, 479-483
Weder 
J., van !
J
J 354
27 Hynes, R. O. (1992) Cell 69, 11-25.
28 van Kooyk, Y., van de Wiel-van Kemenade, P., 
Weder, P., Kuijpers, T. W. and Figdor, C. G. 
(1989) Nature (London) 342, 811-813
29 Dustin, M. L. and Springer, T. A. (1989) Nature 
(London) 341, 619-624
30 Pardi, R., Inverardi, L. and Bender, J. R. (1992)
31
Immunol. Today 13, 224-230
Weder, P.. Heiie. K.. de Waal
Malefijt, R. and Figdor, C. G. (1993) Cell Adhes. 
Commun. 1, 21-32.
32 Dransfield, I. and Hogg, N. (1989) EMBO J. 8, 
3759-3765
33 Hibbs, M. L., Xu, H., Stacker, S. A. & Springer,
T. A. (1991) Science 251, 1611-1613
34 Hibbs, M. L., Jakes, S., Stacker, S. A., Wallace,
R. W. and Springer, T. A. (1991) J. Exp. Med. 174,
1227-1238
35 Kolanus, W., Nagel, W., Schiller, B., Zeitlmann, L., 
Godar, S., Stockinger, H. and Seed, B. (1996) Cell 
86, 233-242
36 Reszka, A. A., Hayashi, Y. and Horwitz, A. F.
(1992) J. Cell Biol. 117, 1321-1330
37 Pardi, R., Bossi, G., Inverardi, L., Rovida, E. and 
Bender, J. R. (1995) J. Immunol. 155, 1252-1263
38 Muir, T. W., Williams, M. J, Ginsberg, M. H. and 
Kent, S. B. I-I. (1994) Biochemistry 33, 7701-7708
39 Du, X., Gu, M., Weisel, J. W., Nagaswami, C , 
Bennett, J. S., Bowditch, R. and Ginsberg, M. H.
(1993) J. Biol. Chem. 268, 23087-23092
40 van Kooyk, Y., Weder, P., Heije, K. and Figdor,
C. G. (1994) J. Cell Biol. 124, 1061-1070
41 Miller, J., Knorr, R., Ferrone, M., Houdei, R., 
Carron, C. P. and Dustin, M. L. (1995) J. Exp. 
Med. 182, 1231-1241
42 Detmers, P. A., Wright, S. D., Olsen, E., Kimball, 
B. and Cohn, Z. A. (1987) J. Cell Biol. 105, 
1137-1145
43 Yamada, K. M. and Miyamoto, S. (1995) Curr. 
Opin. Cell Biol. 7, 681-689
44 Otey, C. A., Vasquez, G. B., Burridge, K. and
W. (1993)J
21193-21197
45
46
J 326
J
C. G. (1997) Mol. Biol. Cell. 8, 341-351
47 J
J. (1996) J
48 Figdor, C. G., van Kooyk, Y. and Keizer, G. D. 
(1990) Immunol. Today 11, 277-280
! 997
Biochemical Society Transactions
49 Kanner, S. B., Grosmaire, L. S., Ledbetter, J. A. Fox, J. W., Vines, R. R. and Parsons, J. T. (1994) 
and Damle, N. K. (1993) Proc. Natl. Acad. Sci. Mol. Cell Biol. 14, 1680-1688
U.S.A. 90, 7099-7103
50 Vuori, K., Hirai, H., Aizawa, S. and Ruoslahti, E.
(1996) Mol. Cell Biol. 16, 2606-2613 ----------------------------------------------------------------------
51 Sehaller, M. D., Hildebrand, J. D., Shannon, J. D., Received 1 November 1996
Peripheral blood fibrocytes: novel fibroblast-like cells that present antigen and 
mediate tissue repair
J. Chesney and R. Bucala*
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Introduction
Wounding is defined as a physical disruption of 
the normal architecture of a tissue and may be 
caused by trauma, burns, inflammatory processes 
or metabolic insufficiency. The host initiates a 
co-ordinated repair response to wounding that 
serves to prevent infection and ultimately
re-establish normal tissue integrity. nm  ■1 his
response to injury involves a complex interplay of 
cellular, humoral and connective tissue elements 
[1,2]. Platelets play an early role by releasing 
factors that are required for both clotting and the 
recruitment of peripheral blood leucocytes to the 
injured site. Peripheral blood leucocytes then 
produce mediators that combat infection and 
co-ordinate successive steps of the tissue repair 
response [1—3]. Connective-tissue cells play a 
critical role in the reparative phase of wound 
healing by secreting extracellular matrix proteins. 
The usual outcome of this cascading series of 
cellular events is elimination of the invasive 
stimulus followed by connective tissue scar for­
mation and, over time, remodelling of the injured 
site.
Connective-tissue fibroblasts are a quiescent 
cell population that under normal circumstances 
remain sparsely distributed throughout the 
extracellular matrix [4]. As a consequence of 
injury, fibroblasts enter and proliferate within the 
injured site [5]. The precise origin of the fibro­
blast-like cells within wounds has been contro-
Abbreviations used: APC, antigen-presenting cell: 
TGF-/H, transforming growth factor / i l ; M-CSF, 
macrophage colony-stimulating factor; MIP, macro- 
phage-inflammatoiy protein; IL, interleukin; TNF-a, 
tumour necrosis factor a.
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versial since the original microscopic studies of 
developing connective tissue performed by Paget 
in 1863 [6,7]. That wound fibroblasts appeared 
by migration from adjacent tissue was supported 
by experiments showing the apparent ingrowth of 
fibroblasts from local areas, and by the observa­
tion that India Ink-tagged monocytes failed to 
develop into tissue fibroblasts in vivo [7,8], 
Other studies, however, reported evidence for the 
differentiation of leucocytes into fibroblasts 
within subcutaneous diffusion chambers and the 
apparent in vitro transformation of peripheral 
blood mononuclear cells into collagen-producing
cells [9,10].
Discovery of peripheral blood fibrocytes
Several years ago, investigations into the 
population present in experimentally implanted 
subcutaneous wound chambers led to the discov­
ery of an adherent proliferating cell type that 
displayed fibroblast properties yet *e
distinct haemopoietic/leucocyte cell-surface 
kers [11]. Wound chambers consist of 
lengths of sponge-filled silastic tubing and are a
frequently employed model for the study of 
tissue-reparative responses in vivo. Implantation 
of these chambers into the subcutaneous space 
of mice results in a rapid infiltration of peri­
pheral blood inflammatoiy cells, including 
neutrophils, monocytes and lymphocytes [12,13]. 
Large numbers of adherent spindle-shaped cells  
that resemble fibroblasts were unexpectedly 
observed to infiltrate wound chambers soon after 
implantation and coincidentally with the appear­
ance of circulating inflammatory cells. D ouble­
immunofluorescence studies showed that, within
implantation, as many as 
;sent in wound-chamber
15% of the
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